Monoclonal proteinaemia and solid tumours

European Journal of Cancer

Volumn 40, Issue 10, 2004, Pages 1539-1544

  Schaar, C G ^a   Snijder, S ^b   Oostindier M J ^b   Rosendaal, F R ^a   Willemze, R ^a   Kluin Nelemans, J C ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Integraal Kankercentrum West   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

M(onoclonal) protein; M(onoclonal) proteinaemia; Paraprotein; Solid tumour; Standardised morbidity ratio (SMR)

Indexed keywords

M PROTEIN;

ARTICLE; CANCER REGISTRY; HEMATOLOGIC MALIGNANCY; HUMAN; MONOCLONAL PROTEINEMIA; PARAPROTEINEMIA; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOLID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PARAPROTEINEMIAS; PREVALENCE;

EID: 2942571355     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.11.038     Document Type: Article

References (19)

1. Creyssel R., Fine J.-.M., Morel P. Etude biochimique de quelques formes atypiques de dysprotéinémies. Rev. Hematol. 14:1959;238-249
2. Osserman E.F., Takatsuki K. Plasma cell myeloma: gamma globulin synthesis and structure. Medicine. 42:1963;357-385
3. Hällén J. Discrete gammaglobulin (M-) components in serum. Clinical study of 150 subjects without myelomatosis. Acta Med. Scand. 462:1966;1-127
4. Danon F., Clauvel J.P., Seligmann M. Les 'paraprotéines' de type IgG et IgA en dehors de la maladie de Kahler. Rev. Fr. Etud.Clin. Biol. 12:1967;681-701
5. Pick A.I., Yeshurun D., Schreibman S., Fleminger R., Kessler H. Monoclonal gammopathy in patients with epithelial tumors. Harefuah. 86:1974;5-13
6. Colls B.M., Lorier M.A. Immunocytoma, cancer, and other associations of monoclonal gammopathy: A review of 224 cases. N. Z. Med. J. 82:1975;221-226
7. Ameis A., Ko H.S., Pruzanski W. M components-a review of 1242 cases. Can. Med. Assoc. J. 114:1976;889-895
8. Bonomo L., Dammacco F., Miglietta A. Paraproteinemia and neoplasia. Ric. Clin. Lab. 15:1985;99-104
9. Ong F., Hermans J., Noordijk E.M., et al. A population-based registry on paraproteinemia in The Netherlands. Comprehensive Cancer Centre West, Leiden, The Netherlands. Br. J. Haematol. 99:1997;914-920
10. Ong F., Hermans J., Noordijk E.M., et al. Developing a population-based registry for patients with paraproteinemias or multiple myeloma. J. Clin. Epidemiol. 50:1997;909-915
11. World Health Organisation (WHO). International Classification of Diseases for Oncology, 1st ed., Geneva, 1976
12. Visser O, Coebergh JWW, Schouten LJ, Dijck JAAM. Incidence of cancer in the Netherlands 1994 and idem 1997. Utrecht, Vereniging van Intergrale Kankercentra
13. Vandenbroucke J.P. A shortcut method for calculating the 95 per cent confidence interval of the standardized mortality ratio. Am. J. Epidemiol. 115:1982;303-304
14. Kyle R.A. Benign monoclonal gammopathy - after 20-35 years of follow-up. Mayo. Clin. Proc. 68:1993;26-36
15. Pasqualetti P., Festuccia V., Collacciani A., Casale R. The natural history of monoclonal gammopathy of undetermined significance. A 5- to 20-year follow-up of 263 cases. Acta Haematol. 97:1997;174-179
16. Gregersen H., Mellemkjaer L., Salling I.J., Sorensen H.T., Olsen J.H., Pedersen J.O., et al. Cancer risk in patients with monoclonal gammopathy of undetermined significance. Am. J. Hematol. 63:2000;1-6
17. Migliore P.J., Alexanian R. Monoclonal gammopathy in human neoplasia. Cancer. 21:1968;1127-1131
18. Talerman A., Haije W.G. The frequency of M-components in sera of patients with solid malignant neoplasms. Br. J. Cancer. 27:1973;276-282
19. Goffinet D.R., Warnke R., Dunnick N.R., et al. Clinical and surgical (laparotomy) evaluation of patients with non-Hodgkin's lymphomas. Cancer Treat. Rep. 61:1977;981-992